Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.
about
Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesSingle-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 virusesPreclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccineGM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primatesProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Development of universal influenza vaccines based on influenza virus M and NP genes.Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model.Adenoviral vectors as novel vaccines for influenza.Heterosubtypic immunity to influenza A virus: where do we stand?Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines.Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched VaccinesDevelopment of adenoviral vector-based mucosal vaccine against influenza.Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus.Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice.Antibodies against conserved antigens provide opportunities for reform in influenza vaccine designBroader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in miceComparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferretRobust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coliProtective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus.Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection.Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virusIntranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune responseProtective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Age Dependence of Immunity Induced by a Candidate Universal Influenza Vaccine in MiceEnhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant.New insights on adenovirus as vaccine vectors.CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.DNA vaccines for targeting bacterial infections.Progress on adenovirus-vectored universal influenza vaccines.Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts.Towards a universal influenza vaccine: different approaches for one goal.Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates.
P2860
Q27013568-FBAAD2A7-54AD-4A4F-8429-674A69E7E5DBQ27318575-2131F5CC-6C90-461A-95FB-269DAF33B403Q27347652-AA465438-CF26-4D4A-B8E0-419482D377CEQ28751705-32CD4FC2-9EC5-4D7A-9E09-C8CCA6FEC5D6Q30226988-B817A29F-EF79-41BA-A799-B63E914D9A1AQ30355116-524A504A-AEB6-4B21-A3B5-0180A6CEC70DQ30360144-E1E06910-1DB0-45D8-84F3-34A32D1F77F5Q30370445-7D77B45C-0078-4AEC-8A2A-6412957538F4Q30370995-EC419196-9B24-41F2-ABE8-1E0FB4AD30DDQ30375714-84D7F758-6646-4548-A557-758F51B37758Q30375991-0178662A-36C1-44DF-8003-F51C53E07D6CQ30384675-848E60A3-0ED5-4F47-90D1-44B19164D971Q30396482-34000E1C-D706-4DA4-88B3-A5821E55FA45Q30396642-7AABAADF-D273-45B8-8F9E-5718D781B6EAQ30399477-789F7468-F7F8-4E98-AE9E-7251DF43536CQ30400347-F95B9DB2-6BBC-4DC2-BAE1-20A190835DFBQ30405211-1B776C35-F4BD-4D23-B619-428DB22ECEA5Q30416502-4F422F23-2593-48D9-96FD-AED60775C4F7Q30418340-564C4AE8-FBFD-4EF3-988F-DBD7454F724DQ30425194-79B7293B-A610-4187-918F-3A05A042145FQ33547457-421FD33B-C654-4AAD-BFEE-46294880E203Q34533990-2AF72EC6-0E67-4F62-BB8F-25DC07058C4AQ34964980-F5F383FF-AE9C-450C-810F-BD253C4EB69DQ35005641-CC0B1F9C-FB90-43C2-BBD1-9054D726A349Q35173733-BDD46454-F767-44F3-808F-953A37381A4EQ35568518-75D6B34C-940B-42B8-898F-5D0D1EFC4FD0Q35656657-31BF09AA-0F29-4999-8D45-A215BCAC32AAQ35982805-48C8B26A-3F03-45B2-A693-0AE0DEC46060Q36851838-0DCC516E-CB9F-49DB-9BB0-598E1FDB3361Q37513550-9105585D-86C5-4F09-ADD6-0953C6070BC3Q37718861-78A1A6D1-D3DD-4573-9EA3-BC66976D3413Q37771943-4CCBAC41-5946-404B-B284-81F214333575Q38421971-30E5DFE0-A5B6-4DA9-B36F-8E221F0DF89EQ41865771-772B9EDF-DE14-4D5B-B16C-87499FA48C59Q47262061-8073491A-D36C-4098-9032-18DE3CDE0CDFQ47548294-12C06590-9247-4480-8D82-CBF526402330Q47548866-0B86353B-D439-42F6-AFFF-24B85488E51AQ47562002-25D440B9-E01E-4F1B-8C82-8E92304FF329
P2860
Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Comparison of vaccines for ind ...... e-adenovirus boost strategies.
@en
Comparison of vaccines for ind ...... e-adenovirus boost strategies.
@nl
type
label
Comparison of vaccines for ind ...... e-adenovirus boost strategies.
@en
Comparison of vaccines for ind ...... e-adenovirus boost strategies.
@nl
prefLabel
Comparison of vaccines for ind ...... e-adenovirus boost strategies.
@en
Comparison of vaccines for ind ...... e-adenovirus boost strategies.
@nl
P2093
P1433
P1476
Comparison of vaccines for ind ...... e-adenovirus boost strategies.
@en
P2093
Chia-Yun Lo
Claudia Pappas
Graeme E Price
Julia A Misplon
Suzanne L Epstein
Wing-Pui Kong
Zhengqi Wu
P304
P356
10.1016/J.VACCINE.2008.02.047
P407
P577
2008-03-13T00:00:00Z